OncoMatch/Clinical Trials/NCT05544136
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Is NCT05544136 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carboplatin for head and neck cancer.
Treatment: Carboplatin — The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A P16 IHC negative (negative)
If the primary site is oropharynx or unknown primary, P16 IHC must be negative.
Disease stage
Required: Stage N2C (AJCC 7th edition)
Clinical stage T0-3 N1-2C M0 (AJCC 7th edition) without evidence of distant metastasis
Prior therapy
Cannot have received: radiation therapy
Must not have received prior radiation therapy or chemotherapy for HNC.
Cannot have received: systemic chemotherapy
Exception: prior chemotherapy for a different non-H&N cancer is permissible
Must not have received prior radiation therapy or chemotherapy for HNC.
Cannot have received: chemotherapy or radiotherapy
Prior chemotherapy or radiotherapy within the last three years.
Lab requirements
Blood counts
WBC ≥ 2,000 cells/µL; ANC ≥ 1,000 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL (transfusion/intervention allowed to achieve Hgb ≥ 8.0 g/dL)
Kidney function
Serum creatinine < 1.5 mg/dL or creatinine clearance (CrCl) ≥ 50 mL/min; patients with serum creatinine > 1.5 mg/dL can be eligible for carboplatin-based chemotherapy with approval of co-PI
Liver function
Bilirubin < 2 mg/dL; AST or ALT < 3 x the upper limit of normal
Adequate hematologic, renal, and hepatic function within 30 days prior to registration, defined as: WBC ≥ 2,000 cells/µL; ANC ≥ 1,000 cells/mm3; Platelets ≥ 100,000 cells/mm3; Hemoglobin ≥ 8.0 g/dL; Serum creatinine < 1.5 mg/dL or CrCl ≥ 50 mL/min; Bilirubin < 2 mg/dL; AST or ALT < 3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify